Haoran Zhang

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study.

Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study.

Journal: Translational lung cancer research

Published: September 30, 2025

The Clinical Characteristics, Treatment, and Prognosis of Lung Cancer in Young Patients in the New Era of Cancer Treatment: A Retrospective and Comprehensive Analysis.

The Clinical Characteristics, Treatment, and Prognosis of Lung Cancer in Young Patients in the New Era of Cancer Treatment: A Retrospective and Comprehensive Analysis.

Journal: Current oncology (Toronto, Ont.)

Published: July 07, 2025

Comparative effectiveness of pembrolizumab-chemotherapy versus chemotherapy with/without bevacizumab in unresectable, locally advanced or metastatic non-small cell lung cancer: a Chinese multicenter real-world analysis emphasizing PD-L1-negative populations.

Comparative effectiveness of pembrolizumab-chemotherapy versus chemotherapy with/without bevacizumab in unresectable, locally advanced or metastatic non-small cell lung cancer: a Chinese multicenter real-world analysis emphasizing PD-L1-negative populations.

Journal: Translational lung cancer research

Published: March 08, 2025

Prognostic Role of Early Dynamic Changes in Neutrophil-to-Lymphocyte Ratio of Nonsmall Cell Lung Cancer Patients.

Prognostic Role of Early Dynamic Changes in Neutrophil-to-Lymphocyte Ratio of Nonsmall Cell Lung Cancer Patients.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: January 21, 2025

Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational study.

Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational study.

Journal: Chinese medical journal

Published: June 13, 2024

Construction of Prognostic Model and miRNA-mRNA Regulatory Network for Lung Squamous Cell Carcinoma.

Construction of Prognostic Model and miRNA-mRNA Regulatory Network for Lung Squamous Cell Carcinoma.

Journal: Alternative therapies in health and medicine

Published: October 19, 2023

Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study.

Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study.

Journal: Translational lung cancer research

Published: September 06, 2023

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC.

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC.

Journal: Thoracic cancer

Published: June 26, 2023

A magnetism/laser-auxiliary cascaded drug delivery to pulmonary carcinoma.

A magnetism/laser-auxiliary cascaded drug delivery to pulmonary carcinoma.

Journal: Acta pharmaceutica Sinica. B

Published: September 12, 2019

Showing 1-9 of 9

Last Updated: 09/26/2026